CytomX Therapeutics Gross Profit

CytomX Therapeutics (CTMX) currently reports a gross profit of $1.6M as of June 2026. That compares with $90M in the prior-year period — down 98.2% year over year. That is below the Healthcare sector average of $66B. Use the charts on this page to explore CytomX Therapeutics's gross profit history and peer comparisons.

CytomX Therapeutics's gross profit decreased from $90M to $1.6M — a 98.2% year-over-year decrease (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

CytomX Therapeutics's gross profit of $1.6M is lower than the Healthcare sector average of $66B. That is roughly 100.0% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

CytomX Therapeutics reported $1.6M in gross profit as of June 2026. That compares with $90M in the prior-year period — down 98.2% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current gross profit of $1.6M, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is $66B. From there, open related valuation or income-statement pages for CytomX Therapeutics, and consider following CTMX for alerts when major investors trade the stock.